Clinical trials: ctDNA Monitoring
Ovarian Cancer Stage IV, Ovarian Cancer Stage III
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments
Patients who receive satisfactory PDS, currently the change in CA125 during chemotherapy can only be used to evaluate the effectiveness of chemotherapy.
- Trial name
- NCT06025045
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jing Li
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
The goal of this clinical trial is to evaluate the efficacy and safety of early secondary infusion of CD19 CAR T-cell therapy in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), guided by ctDNA monitoring.
- Trial name
- NCT06902012
- Testing
- Infusion of Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhujiang Hospital
Diffuse Large B Cell Lymphoma
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells
The purpose of this study is to demonstrate that it is possible to report in real time (less than 3 weeks) to the hematologist the results of the molecular minimal residual disease (MRD) based on blood circulating tumor DNA…
- Trial name
- RT-CAR (NCT05675982)
- Testing
- CAR-T cells monitoring
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Henri Becquerel
Colorectal Neoplasms, Colorectal Cancer (Diagnosis)
MRD Monitoring in Colorectal Cancer Using ctDNA
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy.
- Conditions
- Colorectal Neoplasms, Colorectal Cancer (Diagnosis), Minimal Residual Disease
- Trial name
- RezidRAS (NCT07895459)
- Testing
- Blood draw for ctDNA analysis
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute
Esophageal Cancer, ctDNA
A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring
Esophageal squamous cell carcinoma (ESCC) continues to exhibit high incidence and mortality rates in China, with the majority of patients diagnosed at middle to advanced stages.
- Trial name
- NCT06792786
- Testing
- Induction Immunochemotherapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Central Hospital of Lishui City
Ovarian Cancer
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
This observational study is conducted to assess the utility of circulating tumor DNA in monitoring the response to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer，and evaluate the consistency of circulating…
- Trial name
- NCT05976932
- Testing
- pegylated liposomal doxorubicin
- Volunteers
- 20 people
- Sponsor
- Fudan University
Primary Central Nervous System Lymphoma
Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
The incidence of primary central nervous system lymphoma (PCNSL) has increased steadily, and the disease often progresses rapidly, with many patients presenting in critical condition.
- Trial name
- NCT07851363
- Testing
- HD-MTX-based chemotherapy, BTK inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiaohui Ren
Colorectal Cancer
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
The aim of this clinical trial is to test whether minimal residual disease (MRD) status detected by circulating tumor DNA (ctDNA) could be used to guide precision therapy of post-surgery in colon cancer.
- Trial name
- MIRROR (NCT06204484)
- Testing
- CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Sun Yat-sen University